Xwell, Inc. (XWEL) — SEC Filings
Xwell, Inc. (XWEL) — 50 SEC filings. Latest: EFFECT (Apr 16, 2026). Includes 29 8-K, 6 10-Q, 4 DEF 14A.
Overview
Xwell, Inc. (XWEL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 1, 2026: XWELL, Inc. filed an 8-K on April 1, 2026, reporting its financial results and condition. The filing includes financial statements and exhibits, with the primary document being the 8-K itself.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 7 bullish, 4 bearish, 34 neutral, 5 mixed. The dominant filing sentiment for Xwell, Inc. is neutral.
Filing Type Overview
Xwell, Inc. (XWEL) has filed 1 EFFECT, 29 8-K, 2 10-K, 4 DEF 14A, 6 10-Q, 3 DEFA14A, 1 10-K/A, 2 SC 13D/A, 1 SC 13G, 1 SC 13D with the SEC between May 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of XWEL's 48 recent filings, 5 were flagged as high-risk, 22 as medium-risk, and 21 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Ezra T. Ernst
- Bruce T. Bernstein
- Robert Weinstein
- Galle Wizenberg
- Michael Lebowitz
- Lauren Deutsch
- Michelle Peluso
- David M. Rone
- Barry Goldstein
- Adam Schacter
- Scott Salmirs
- Jessica Chen
- Michael J. DeMarco
- David M. Masi
- Michael J. McShane
Industry Context
XWELL operates in the wellness services sector, with a specific focus on travelers in airport and off-airport locations. The industry is competitive, with players offering a range of services from spa treatments to health testing. The shift towards health and wellness services has been a growing trend, accelerated by recent global health events. However, the travel industry's volatility, influenced by economic conditions and global events, poses a significant challenge.
Top Tags
Acquisition (11) · XWELL (10) · M&A (8) · Private Equity (7) · corporate-governance (6) · financials (5) · Corporate Governance (4) · Merger (4) · Healthcare Services (4) · New Mountain Capital (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CDC Contract Base Value | $22.2M | New three-year contract for XpresTest, providing a significant revenue stream. |
| CDC Contract Maximum Ceiling | $24.8M | Potential maximum revenue from the three-year CDC biosurveillance contract. |
| Naples Wax Center Acquisition Cost | $1.624M | Purchase price for Naples Wax Center on September 12, 2023, part of off-airport expansion. |
| Domestic XpresSpa Locations | 16 | Number of XpresSpa locations in the U.S. as of December 31, 2025. |
| International XpresSpa Locations | 9 | Number of XpresSpa locations outside the U.S. as of December 31, 2025. |
| Shares Outstanding | 7,926,766 | Total common stock shares outstanding as of March 26, 2026. |
| Market Value of Non-Affiliate Stock | $3.63M | Aggregate market value as of June 30, 2025, indicating a small market capitalization. |
| Purchase Price | $100 million | Aggregate price for Carelon Behavioral Health acquisition |
| Expected Closing | Q1 2026 | Target timeframe for the acquisition to be finalized |
| Per Share Acquisition Price | $7.00 | cash consideration offered to XWELL shareholders |
| Total Transaction Value | $300 million | includes assumption of net debt |
| Threshold for Common Stock Issuance | 19.99% | Issuance of common stock underlying Series G Preferred Stock, Warrants, and Notes could exceed this percentage of outstanding common stock, triggering Nasdaq Listing Rule 5635(d) approval. |
| Reverse Stock Split Ratio Range | 1-for-2 to 1-for-20 | The Board has discretion to implement a reverse stock split within this range to potentially boost share price and maintain Nasdaq listing. |
| Annual Meeting Date | December 18, 2025 | Date when stockholders will vote on key proposals including director elections, auditor ratification, executive compensation, board classification, reverse stock split, and equity issuance. |
| Record Date | November 6, 2025 | Date by which stockholders must hold shares to be eligible to vote at the Annual Meeting. |
Frequently Asked Questions
What are the latest SEC filings for Xwell, Inc. (XWEL)?
Xwell, Inc. has 50 recent SEC filings from May 2024 to Apr 2026, including 29 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XWEL filings?
Across 50 filings, the sentiment breakdown is: 7 bullish, 4 bearish, 34 neutral, 5 mixed. The dominant sentiment is neutral.
Where can I find Xwell, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xwell, Inc. (XWEL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xwell, Inc.?
Key financial highlights from Xwell, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XWEL?
The investment thesis for XWEL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xwell, Inc.?
Key executives identified across Xwell, Inc.'s filings include Ezra T. Ernst, Bruce T. Bernstein, Robert Weinstein, Galle Wizenberg, Michael Lebowitz and 14 others.
What are the main risk factors for Xwell, Inc. stock?
Of XWEL's 48 assessed filings, 5 were flagged high-risk, 22 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Xwell, Inc.?
Forward guidance and predictions for Xwell, Inc. are extracted from SEC filings as they are enriched.